Gary S. Jacob, Ph.D.
Chairman and Director
Gary S. Jacob, Ph.D. has served as Chairman and Director of Hepion since May 2013. Dr. Jacob served as Chief Executive Officer of Callisto Pharmaceuticals, Inc. from May 2003 until January 2013 and a director from October 2004 until January 2013. Dr. Jacob currently serves as a director of Trovagene, Inc., a public diagnostics company and a director and Chief Executive Officer of Synergy Pharmaceuticals Inc. since July 2008. Dr. Jacob has over twenty-five years of experience in the pharmaceutical and biotechnology industries across multiple disciplines. Learn More >>
Robert Foster, B.Sc. (Pharm), Pharm.D., Ph.D.
Chief Executive Officer
Dr. Foster first began working on cyclophilin in 1988, and brings more than 30 years of pharmaceutical and biotech experience to Hepion. Prior to Hepion, he was CEO and Founder of Ciclofilin Pharmaceuticals Inc., which merged with Hepion in 2016. He founded Isotechnika Pharma Inc. (TSX:ISA) in 1993, and was its Chairman and CEO for approximately 21 years. Dr. Foster was founding CEO, and later CSO, of Aurinia (NASDAQ:AUPH) after it was acquired by Isotechnika. During his tenure at Isotechnika, Dr. Foster, together with a core team, discovered the immunosuppressive drug voclosporin. Learn More >>
John P. Brancaccio
John P. Brancaccio, a retired C.P.A., has served as a Director of our company since May 2013. Since April 2004, Mr. Brancaccio has been the Chief Financial Officer of Accelerated Technologies, Inc., an incubator for medical device companies. From May 2002 until March 2004, Mr. Brancaccio was the Chief Financial Officer of Memory Pharmaceuticals Corp., a biotechnology company. From 2000 to 2002, Mr. Brancaccio was the Chief Financial Officer/Chief Operating Officer of Eline Group, an entertainment and media company. Learn More >>
Timothy M. Block, Ph.D.
Timothy M. Block, Ph.D., has served as a Director of our company since October 2013. Dr. Block currently serves as Co-founder and President of the Hepatitis B Foundation (HBF) and its Baruch S. Blumberg Institute (formerly called the Institute for Hepatitis and Virus Research), the nation’s leading nonprofit organizations dedicated to improving the lives of those affected worldwide through research, education and patient advocacy. He also serves as President and CEO of the Pennsylvania (PA) Biotechnology Center. Learn More >>
Arnold Lippa, Ph.D.
Dr. Lippa has been Executive Chairman of the Board of Cortex Pharmaceuticals Inc., since March 2013, and was appointed Chief Scientific Officer in August 2015. Previously, he served as Chief Executive Officer and President. He is also Chairman of the Board of Xintria Pharmaceutical Corporation, which he co-founded in 2006. Dr. Lippa is a Managing Member and founder of T Morgen Capital LLC, which is an investment and management company specializing in the creation and management of biomedical companies. Learn More >>
Thomas H. Adams, Ph.D.
Thomas H. Adams, Ph.D. currently serves as Chairman of the Board for Trovagene Inc., a director of Synergy Pharmaceuticals, Inc. and a director and Chief Technology Officer of IRIS International, Inc. Dr. Adams served as Chairman and Chief Executive Officer of Leucadia Technologies, a privately held medical-device company, from 1998 to 2006, when Leucadia was acquired by IRIS. Dr. Adams has significant public-company experience serving as a director of Invitrogen from 2000 to 2002. Learn More >>
Peter LJ Wijngaard, Ph.D.
Peter LJ Wijngaard, Ph.D., has served as a Director of our company since June 2020. Dr. Wijngaard is currently the Chief Development Officer at The Medicines Company which was acquired by Novartis in January 2020 for $9.7B USD. He has more than 25 years of experience in the pharmaceutical industry working for Sandoz, Pharmacia, F. Hoffmann-La Roche, Viropharma and The Medicines Company in various roles in Product Development, Medical Affairs and Business Development. Learn More >>
Hepion Pharmaceuticals, Inc.’s Board of Directors approved the Anonymous Ethics and Compliance Hotline on December 9, 2015 which is effective as of January 1, 2016.
Hepion Pharmaceuticals, Inc. promotes a trustworthy and honest work environment and reinforces the vision of these ethics within the organization. Hepion Pharmaceuticals, Inc. will not tolerate any wrongdoing or impropriety and takes allegations of fraud, waste and abuse very seriously. Hepion Pharmaceuticals, Inc. is committed to achieving the highest possible standards of ethics and behavior in its corporate governance and workplace.
It is Hepion Pharmaceuticals, Inc.’s policy to comply with all applicable laws and to protect employees against unlawful discrimination or retaliation by their employer as a result of their lawfully reporting information regarding, or their participation in, investigations involving violations by Hepion Pharmaceuticals, Inc. or its agents of federal or state law.
In order to facilitate the reporting of complaints, Hepion Pharmaceuticals, Inc. has established this whistleblower hotline through Lighthouse Services, Inc. If you have a matter that you wish to bring to our attention, please select one of the following methods to report your complaints or concerns.
- English speaking USA and Canada: 855-850-0005
- Spanish speaking USA and Canada: 800-216-1288
- Spanish speaking Mexico: 01-800-681-5340
- French speaking Canada: 855-725-0002
- Website: www.lighthouse-services.com/hepionpharma
- E-mail: email@example.com (must include company name with report)
- Fax: (215) 689-3885 (must include company name with report)
Lighthouse toll free number and other methods of reporting are available 24 hours a day, 7 days a week. Complaints should be as detailed and complete as possible and include references to any supporting documentation in order to allow effective and efficient investigation thereof. Hepion Pharmaceuticals Inc.’s Audit Committee will oversee investigation and treatment of employee concerns collected. Unless you choose to provide it, personally identifiable information remains confidential.